Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).
about
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's diseaseRational pharmacological approaches for cognitive dysfunction and depression in Parkinson's diseaseParkinson Disease and Dementia.Treatment of psychosis and dementia in Parkinson's disease.Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of PennsyThe Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's diseaseEffects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial.Parkinson's psychosis.The interplay between gait, falls and cognition: can cognitive therapy reduce fall risk?Effect of augmenting cholinergic function on gait and balanceParkinson's disease dementia: a neural networks perspective.Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.Outcome measures for Parkinson's disease dementia: a systematic review.The role of phytochemicals in the treatment and prevention of dementia.Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor.Drug treatments for the neuropsychiatric complications of Parkinson's disease.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials.Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis.Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.Neuropsychiatric Issues in Parkinson's Disease.Clinical Epidemiology, Evaluation, and Management of Dementia in Parkinson Disease.Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism.Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature.Recent advances in the assessment and treatment of falls in Parkinson's disease.Milestones in gait, balance, and falling.Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease.Late (Complicated) Parkinson's Disease
P2860
Q24201307-3C100295-5A4C-4D84-AC09-DC8FE5C6C8CAQ28084380-FEB6CEF4-A2D4-482D-967F-7E1782D39786Q30248574-A11FE176-C4AC-446A-BC77-C8CA6FAA16F0Q30358337-1BC4C8DD-C07D-48E4-854D-15B38646CFC6Q30538175-AFC102CC-59DD-41EC-B170-A94C7D17F8EEQ33607256-EC7F8ECA-56D7-44FA-93E6-132240EB0D05Q34032505-5D6604F7-721E-48AA-91D5-597BBD473EECQ34378145-6FA790C2-A0F1-412D-AC18-412B48641260Q34610632-06DBB0CB-BAF8-424E-9FC4-B50F6A649C9DQ35186701-07976D6A-0D6B-4CB1-95A8-C3FCE7D3BB20Q35876410-9D3495A9-AE72-44DA-9B02-90759E29879BQ36186763-F59D1024-1291-4AC1-8029-9B9116D2D326Q36351543-8DAD976D-C7F2-4D74-AF3A-936B080B8BA4Q36688859-BCD2B68D-5134-419B-8F7A-406EB7386323Q37884566-D2E8468F-5A3F-4F82-B869-E2F635B6E1A9Q37902895-BE20CCAA-9463-4D99-8DB6-923738D2B9D0Q38067142-7C8095A5-9B1C-4477-B2D3-1028C22DD039Q38070888-AC0B020C-D53B-4541-9847-8EEA01507DF1Q38391306-49B5D3D2-82A6-496A-807A-314B3F393036Q38556646-ECCED782-57D3-468A-BA20-5349296C0AE7Q38661735-F29732AB-9549-487C-AAE1-CB3436427CE1Q38799051-21C22E46-C6D0-4E1B-9A0E-B4F2E2FC74AFQ38863643-34B8C068-FE25-492A-9515-FA6427C29C6DQ39432789-50416F25-D6A2-4211-87AA-5F030A907DABQ39457831-4A5F1BD4-5E87-4545-8CF6-82CF8335745BQ42363799-B89E4B8F-759A-4712-B321-BC8AE5A9F971Q48659938-9E275E08-28A1-4640-ACD2-D72F2DCAA97EQ54975082-2F149FF8-78C1-446A-AE63-3E8453180F34Q58870320-067837A9-680A-4DF1-B7B6-6CD8D6AB2C02
P2860
Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Efficacy and safety of galanta ...... se (an open controlled trial).
@en
Efficacy and safety of galantamine
@nl
type
label
Efficacy and safety of galanta ...... se (an open controlled trial).
@en
Efficacy and safety of galantamine
@nl
prefLabel
Efficacy and safety of galanta ...... se (an open controlled trial).
@en
Efficacy and safety of galantamine
@nl
P2093
P2860
P1476
Efficacy and safety of galanta ...... se (an open controlled trial).
@en
P2093
A Yu Emelin
I V Litvinenko
M M Odinak
V I Mogil'naya
P2860
P304
P356
10.1007/S11055-008-9077-3
P577
2008-11-01T00:00:00Z